Treatment of anovulatory anoestrous postpartum dairy cows with a gonadotropin-releasing hormone (GnRH), prostaglandin F2 alpha, GnRH regimen or with progesterone and oestradiol benzoate

AIM: To compare 2 treatments for anovulatory anoestrus (AA) in postpartum dairy cows. The treatments were combinations of gonadotropin-releasing hormone (GnRH) and prostaglandin F2 (PG) or progesterone (P4) and oestradiol benzoate (ODB). METHODS: Forty AA cows from each of 5 herds were blocked by age (2 or 2 years old) and randomly assigned to 1 of 2 treatments. The first group (GPG) were treated with 250 mug of a GnRH analogue, gonadorelin, followed 7 days later by 15 mg of the PG analogue, luprostiol. Two days later the cows were injected with 250 mug of gonadorelin. Cows were artificially inseminated 16-24 h after the second GnRH injection. The second group (P4+ODB) were treated with an intravaginal P4 releasing device for 6 days, followed 24 h after device removal by injection of 1 mg of ODB. Cows were pregnancy tested 35-40 days after the initial insemination and twice again at 6-8 week intervals thereafter. RESULTS: There was no significant difference between P4+ODB and GPG groups in the percentage of cows submitted for insemination in the first 7 days (94.0% vs 100% for P4+ODB vs GPG, respectively; p>0.3), in conception rate to first insemination within the first 7 days (43.6% vs 35.0% for P4+ODB vs GPG, respectively; p>0.2), in the percentage of cows conceiving in the first 28 days of the breeding period (68.0% vs 58.3%, P4+ODB vs GPG, respectively; p>0.1), or in median interval from the end of treatment to conception (20 vs 21 days; p>0.1). CONCLUSIONS: No differences in the reproductive performance of AA cows treated with either P4+ODB or GPG were detected. However, given the small number of animals enrolled, further data are required before the GPG protocol can be recommended for treatment of AA cows.     

Treatment of cystic ovarian disease in dairy cattle

Fourty-four Holstein Friesian cows diagnosed as having ovarian follicular cysts from rectal palpation of the ovaries and observation of estrous behavior were used for the present experiments. Of the 16 cows injected intramuscularly (i.m.) with 110 mg of depot-progestins containing 100 mg of 17alpha-hydroxyprogesterone caproate and 10 mg of progesterone in oil, 8 cows responded with conception with 103 +/- 53 days in average after the treatment. The 8 cows not responding to depot-progestins were injected i.m. with 6,000 MU of HCG on the 10th day after the treatment. As a result, 2 cows of them conceived within 72 days in average after the initial treatment. Of the other 16 cows injected i.m. with 100 mg of progesteron in oil, 3 cows conceived. Interval between the treatment and conception was 36 +/- 9 days in average. In the 11 cows which failed to respond to progesterone treatment, an intramuscular injection of 6,000 MU of HCG on the 5th day after treatment resulted in conception of 7 cows within 42 +/- 10 days in average after the first treatment. Of the remaining 12 cows which received an i.m. injection with 10,000 MU of HCG, 4 cows responded with conception with 64 +/- 51 days in average after treatment. No remarkable rise in serum progesterone levels was observed either 10 days after depot-progestins injection or 5 days after progesterone treatment. Serum progesteron levels increased distinctly after HCG injections. The combined treatment with 100 mg of progesterone and 6,000 MU of HCG at 5 days interval gave the most successful results and this treatment was effective even when performed long after calving. Thus this method of treatment of cystic ovarian disease may be recommended for practical application.     

Fertility parameters of dairy cows with cystic ovarian disease after treatment with gonadotrophin-releasing hormone

Fertility data were collected every four weeks for 10 years from 40 herds of Holstein-Friesian dairy cattle. The data collected during 925 lactations from cows with cystic ovarian disease which were treated with 500 microg gonadorelin were compared with data from a control group of 13,869 normal lactations. The intervals between parturition and first insemination and between parturition and conception were significantly shorter (P<0.001) in the normal cows, but the interval between first insemination and conception was not. The overall conception rate tended to be higher (P<0.10) in the normal cows, but the conception rate after the first insemination was significantly higher (P<0.001) and the number of services per conception was significantly lower (P=0.008) in the normal cows.     

Treatment of anovulatory anoestrous postpartum dairy cows with a gonadotropin-releasing hormone (GnRH), prostaglandin F2𝛂, GnRH regimen or with progesterone and oestradiol benzoate

AIM: To compare 2 treatments for anovulatory anoestrus (AA) in postpartum dairy cows. The treatments were combinations of gonadotropin-releasing hormone (GnRH) and prostaglandin F_2𝛂 (PG) or progesterone (P4) and oestradiol benzoate (ODB).

METHODS: Forty AA cows from each of 5 herds were blocked by age (2 or >2 years old) and randomly assigned to 1 of 2 treatments. The first group (GPG) were treated with 250 𝛍g of a GnRH analogue, gonadorelin, followed 7 days later by 15 mg of the PG analogue, luprostiol. Two days later the cows were injected with 250 𝛍g of gonadorelin. Cows were artificially inseminated 16–24 h after the second GnRH injection. The second group (P4+ODB) were treated with an intravaginal P4 releasing device for 6 days, followed 24 h after device removal by injection of 1 mg of ODB. Cows were pregnancy tested 35–40 days after the initial insemination and twice again at 6–8 week intervals thereafter.

RESULTS: There was no significant difference between P4+ODB and GPG groups in the percentage of cows submitted for insemination in the first 7 days (94.0% vs 100% for P4+ODB vs GPG, respectively; p>0.3), in conception rate to first insemination within the first 7 days (43.6% vs 35.0% for P4+ODB vs GPG, respectively; p>0.2), in the percentage of cows conceiving in the first 28 days of the breeding period (68.0% vs 58.3%, P4+ODB vs GPG, respectively; p>0.1), or in median interval from the end of treatment to conception (20 vs 21days;p>0.1).

CONCLUSIONS: No differences in the reproductive performance of AA cows treated with either P4+ODB or GPG were detected. However, given the small number of animals enrolled, further data are required before the GPG protocol can be recommended for treatment of AA cows.     

Clinical response of dairy cattle with ovarian cysts to single or repeated treatments of gonadotropin-releasing hormone.

Two hundred twenty-five dairy cows with ovarian cysts were treated with 100 microgram of gonadotropin-releasing hormone (GnRH). Cows failing to recover were retreated with a second or third dose of GnRH. Clinical recovery following 1st, 2nd, and 3rd treatments was 76% (170/225), 78% (43/55), and 66% (8/12), respectively. Of the 221 cows that recovered, 184 eventually became pregnant. The remaining 41 cows were culled primarily as problem breeders. First-service conception rate was 49%. More ovarian cysts were detected in herds examined at 2-week intervals than in herds examined at 4-week intervals. The increased diagnosis of ovarian cysts may have been related to detection of cysts prior to spontaneous recovery that occurs in some cases. Clinical recovery from ovarian cysts was lower in herds examined at 2-week intervals following treatment, compared with those examined at 4-week intervals. The GnRH-induced luteinization of ovarian cysts and response to treatment was more difficult to judge at 2 weeks than at 4 weeks.     

Risk factors associated with cystic ovarian disease in Norwegian dairy cattle

Background

The aims of this study were to establish the incidence of cystic ovarian disease (COD) and its geographical and seasonal variation in Norway, investigate the effect of COD on culling rates, and describe the effects of COD on subsequent reproductive performance and its association to twins.

Methods

Diagnosis of COD was made by veterinary surgeons in the field. Four statistical models were made all including herd as random effect: The four different dependent variables investigated were: 1) Diagnosis of COD between 40 and 165 days in milk or not; (n = 511,657); 2) Twins or singleton; data restricted to lactations with new calving (n = 156,661): 3) Culling/removal or not (n = 573,184): 4) Culling due to reproductive problems; data included only lactations which ended in culling (n = 234,232). Model 1, 3 and 4 applied Cox regression models, and model 2 logistic regression. Independent variables were parity, twins/singletons, calving season, herd size, region, COD occurrence in present lactation (if not dependent), and COD diagnosis in previous lactation.

Results

The incidence was 0.82% per lactation. COD increased with increasing parity, was smallest at herd size between 35 and 85 cows. Cows in 1^st parity and calved in spring had lowest hazard of COD and hazard for COD diagnosis was highest in autumn with HR = 2.6 (1.9 - 3.4) compared to spring. There was an interaction between parity and season. COD incidence was lower south of 60°N. Cows which experienced COD had an increased odds of giving birth to twins OR = 2.2 (1.7 - 2.7). Of those that were culled, those with COD were culled more frequently because of reproductive problems; HR = 2.1 (1.9 - 2.3) for higher parity than 2. Having COD diagnosed in the preceding lactation was a hazard for diagnosis in the lactation studied.

Conclusion

COD diagnosis is strongly associated with season (autumn calving) and parity. Herds north of 60°N have more COD. Occurrence of COD is associated with twin births as well as culling due to reproduction.     

Influence of negative energy balance on the reproductive performance after treatment of cystic ovarian disease with gonadotrophin-releasing hormone in dairy cows

The aim of this study was to investigate whether a significant relation exists between the presence of a negative energy balance (NEB) in cows early in lactation and the reproductive performance after treatment with gonadotrophin-releasing hormone of cows with clinical cystic ovarian disease. Reproductive performance after treatment was assessed from the interval between treatment and first insemination (ITFI) and the interval between treatment and conception (ITC). Based on the outcome of the daily change of milk fat yield (Deltafatg) between the first and second milk recordings post-partum, cows were considered to have passed the NEB nadir (positive Deltafatg) or not (negative Deltafatg). Lactations (n = 430) were divided into four groups according to the interval between calving and first milk recording (ICMR): (i) 0-9 days; (ii) 10-19 days; (iii) 20-29 days; (iv) 30-49 days. The relation between a NEB-proxy parameter (Deltafatg) and reproductive performance was determined. A significant interaction existed for groups 1 and 3 (ICMR on 0-9 and 20-29 days post-partum respectively) with an increased and a decreased probability of being inseminated the first day after treatment (ITFI) respectively. However, no significant interaction was found between Deltafatg and the groups with regard to ITC.     

Successful use of a gonadotropin-releasing hormone (GnRH) analog for the treatment of tertiary hypogonadism (GnRH deficiency) in a 5-year-old Belgian Blue bull

A bull was referred for a progressive oligoasthenotheratozoospermia that resulted in a unsuitable seminal quality for the cryopreservation. Breeding soundness evaluation results suggested gonadal dysfunction. Because of the lack of normal ranges for these hormones in the bull, in this study, the hypogonadism and the site of the dysfunction (hypothalamus) were diagnosed by the gonadotropin-releasing hormone (GnRH) stimulation test. The evaluation of pituitary and testicular responsiveness by a GnRH stimulating test revealed a responsiveness of the pituitary and testis, thus a secondary hypogonadism (hypothalamic hypogonadism) was postulated and a therapeutic approach based on the subcutaneous administration of GnRH analog was attempted. An increase in semen volume, concentration and sperm characteristics were detected 9 weeks after the start of the treatment, corroborating the hypothalamic origin of the disease and the useful of the GnRH therapy.     

The therapeutic effects of a progesterone-releasing intravaginal device (PRID) with attached estradiol capsule on ovarian quiescence and cystic ovarian disease in postpartum dairy cows

The objective of this study was to evaluate the effects of a progesterone-releasing intravaginal device (PRID) containing an estradiol benzoate capsule on ovarian dysfunction, including ovarian quiescence, follicular cyst (FC) and luteal cyst or cystic corpus luteum (LC/CCL), in postpartum dairy cows. These ovarian dysfunctions were examined by palpation per rectum relative to plasma progesterone status. The results of clinical examination and hormone assay determined ovarian quiescence in 13 cows, FC in 15 cows and LC/CCL in 7 cows. These cows were treated with PRID for 12 d and then clinical examination was performed. After PRID removal, the proportion of cows exhibiting estrous signs within 7 d and confirmed formation of CL within 7-14 d (markedly effective) were 69.2 % (n=9) for ovarian quiescence, 46.7 % (n=7) for FC, and 28.6 % (2 cows) for LC/CCL. Two cows (15.4 %) in ovarian quiescence, 5 cows (33.3%) with FC and 4 cows (57.1 %) with LC/CCL did not exhibit estrous signs but were recognized as having formed CL within 12-16 d after removal of PRID (effective). These results suggest that treatments of PRID with estradiol benzoate for 12 d have therapeutic efficacy on ovarian dysfunction including ovarian quiescence, FC and LC/CCL in postpartum dairy cows.     

Ovarian and endocrine responses associated with the treatment of cystic ovarian follicles in dairy cows with gonadotropin releasing hormone and prostaglandin F2alpha, with or without exogenous progesterone

The objectives of this observational study were to document ovarian and endocrine responses associated with the treatment of cystic ovarian follicles (COFs) in dairy cows, using gonadotropin releasing hormone (GnRH) and prostaglandin F2alpha (PGF) with or without exogenous progesterone. A secondary objective was to determine pregnancy establishment following synchronization of ovulation and timed insemination in cows diagnosed with COFs. In trial I, 18 Holstein cows diagnosed with COFs received 2 injections of 100 microg GnRH, 9 d apart, with 25 mg PGF given 7 d after the 1st GnRH. A new follicle developed in all 18 cows after the 1st GnRH, and 83% of cows ovulated following the 2nd GnRH. Cows were inseminated 16 h after the 2nd GnRH. Of the 17 cows available for pregnancy diagnosis, 7 were confirmed pregnant. In trial II, 8 cows with COFs received GnRH and an intravaginal progesterone device (CIDR) concurrently, then PGF 7 d later. The CIDR was removed 2 d after PGF administration. Plasma estradiol concentrations declined following CIDR insertion. In all cows, a new follicle developed following GnRH treatment; estradiol-surge and estrus occurred spontaneously after CIDR-removal. Seven of 8 cows ovulated the new follicle. In dairy cows diagnosed with COFs, treatment with GnRH followed by PGF 7 d later, with or without exogenous progesterone, resulted in the recruitment of a healthy new follicle; synchronization of ovulation and timed insemination resulted in a 41% pregnancy rate.     

The effect of intramuscular injection of dinoprost or gonadotropin-releasing hormone in dairy cows on beef quality

Intramuscular injections of drugs and vaccines cause tissue damage and subsequent effects on tenderness and consumer acceptability of beef. In the 2007 National Market Cow and Bull Beef Quality Audit, 100% of plants reported fabricating subprimal cuts such as rib eyes and tenderloins from cow and bull carcasses. Dairy beef quality should therefore be a consideration when injections are given to dairy animals. The discussion about injection site reactions and tenderness has focused on vaccines and antimicrobial drugs with little concern for the effects of reproductive hormones. The objective of this study was to quantify antemortem the effects of semimembranosis/semitendinosis muscle injection of dinoprost and GnRH in lactating dairy cows by estimating the weight of tissue damaged and comparing that with a drug known to cause extensive tissue damage, flunixin meglumine. Tissue damage was estimated from previously reported equations for grams of muscle tissue damage based on area under the curve of serum concentrations of the muscle enzyme creatine kinase over time. Dinoprost and flunixin injection both caused a significantly increased estimate of muscle tissue damaged compared with needle only (P = 0.0351 and 0.0355, respectively). Dinoprost and flunixin caused a marginally significant increased muscle tissue damage compared with GnRH (P = 0.1394 and 0.1475, respectively). No statistically significant difference was found between the estimated weight of muscle tissue damaged by flunixin compared with dinoprost (P = 1.0000), or by saline compared with GnRH (P = 0.7736) or needle only (P = 0.4902). The assumption that reproductive hormones are less damaging than vaccines and antimicrobial drugs should be examined more closely, including postmortem evaluation of injection site lesions and effects on tenderness.     

Synchronising ovulation in dairy cows with either two treatments of gonadotropin-releasing hormone and one of prostaglandin, or two treatments of prostaglandin

OBJECTIVE: To compare oestrus synchronisation using two treatments of gonadotropin-releasing hormone (GnRH) and one of prostaglandin F2 alpha (PG) with a double prostaglandin synchronisation protocol under southern Australian conditions. DESIGN: A clinical trial. PROCEDURE: Eight hundred and forty, seasonally calving, lactating dairy cows within nine herds in the Tallangatta district of northeast Victoria were randomly allocated to treatment and control groups. The treatment (GnRH) group received gonadotropin-releasing hormone followed by prostaglandin F2 alpha and then a second treatment with gonadotropin-releasing hormone. These cows were inseminated at a fixed time after the second gonadotropin-releasing hormone treatment. Cows in the control (PG) group received two injections of prostaglandin F2 alpha, 14 days apart, and were inseminated according to detected oestrus. RESULTS: The effect of GnRH treatment on first service conception rate (CRS1) and 30 day pregnancy rate (PR30) varied between herd (P < 0.001 and P < 0.02, respectively). A significant difference in CRS1 between treatment (GnRH) and control (PG) groups existed in pooled data from eight of the nine herds (38.1% vs 65.9%, P < 0.001). A significant difference also existed in PR30 between treatment (GnRH) and control (PG) groups in pooled data from eight of the nine herds (64.1% vs 72.4%, P = 0.03). Pregnancy rates after 56 days of mating for both groups were not significantly different (79.8% vs 84.1%, P = 0.13 for treatment (GnRH) and control (PG) groups, respectively). Submission rates (proportion of cows submitted for insemination) for the treatment (GnRH) groups were 100%. There was significant variation in submission rates in the control (PG) groups. CONCLUSION: The GnRH protocol may be of benefit in herds where a poor response to the double prostaglandin program is anticipated. However, in the majority of herds in this trial, the double prostaglandin program achieved better results with fewer inseminations.     

In vitro effects of gonadotropin-releasing hormone (GnRH) on Leydig cells of adult alpaca (Lama pacos) testis: GnRH receptor immunolocalization, testosterone and prostaglandin synthesis, and cyclooxygenase activities

The main objective of this study was to examine the modulatory in vitro effects of gonadotropin-releasing hormone (GnRH) on isolated Leydig cells of adult alpaca (Lama pacos) testis. We first evaluated the presence of GnRH receptor (GnRHR) and cyclooxygenase (COX) 1 and COX2 in alpaca testis. We then studied the in vitro effects of buserelin (GnRH analogue), antide (GnRH antagonist), and buserelin plus antide or inhibitor of phospholipase C (compound 48/80) and COXs (acetylsalicylic acid) on the production of testosterone, PGE(2), and PGF(2α) and on the enzymatic activities of COX1 and COX2. Immunoreactivity for GnRHR was detected in the cytoplasm of Leydig cells and in the acrosomal region of spermatids. COX1 and COX2 immunosignals were noted in the cytoplasm of spermatogonia, spermatocytes, spermatids, Leydig cells, and Sertoli cells. Western blot analysis confirmed the GnRHR and COX1 presence in alpaca testis. The in vitro experiments showed that buserelin alone increased (P < 0.01) and antide and buserelin plus acetylsalicylic acid decreased (P < 0.01) testosterone and PGF(2α) production and COX1 activity, whereas antide and compound 48/80 counteracted buserelin effects. Prostaglandin E(2) production and COX2 activity were not affected by buserelin or antide. These data suggest that GnRH directly up-regulates testosterone production in Leydig cells of adult alpaca testis with a postreceptorial mechanism that involves PLC, COX1, and PGF(2α).     

Increased testosterone secretion in bulls treated with a luteinizing hormone releasing hormone (LHRH) agonist requires endogenous LH but not LHRH

The requirement for endogenous LHRH and LH action in the maintenance of elevated plasma concentrations of testosterone in bulls receiving the LHRH agonist deslorelin was examined. In Experiment 1, bulls were either (i) left untreated (control); (ii) implanted with deslorelin; (iii) actively immunized against LHRH; or (iv) implanted with deslorelin and immunized against LHRH. Experiment 2 was of similar design to Experiment 1, except that bulls were immunized against LH in place of LHRH. In Experiment 1, plasma LH declined in bulls immunized against LHRH, but not in the bulls immunized against LHRH and implanted with deslorelin. Also in Experiment 1, plasma testosterone declined in bulls immunized against LHRH but was elevated in bulls treated with deslorelin and bulls treated with deslorelin and immunized against LHRH. In Experiment 2, bulls immunized against LH and treated with deslorelin had plasma concentrations of testosterone similar to controls, whereas bulls treated only with deslorelin had elevated plasma testosterone. It was concluded from these experiments that endogenous LHRH action was not required for increased steroidogenic activity in bulls treated with a LHRH agonist. However, circulating LH was necessary for increased plasma testosterone in bulls implanted with deslorelin. LH is therefore involved in mediating the response of bulls to treatment with deslorelin, either by acting directly at the testes or through a permissive role that allows a direct action of deslorelin at the testes.     

Effect of dietary energy, body condition and calf removal on pituitary gonadotropins, gonadotropin-releasing hormone (GnRH) and hypothalamic opioids in beef cows

Beef cows (n = 64) were slaughtered to evaluate effects of dietary energy and calf removal (CR) on hypothalamic and adenohypophysial endocrine characteristics. From d 190 of gestation until parturition, cows received maintenance (ME; n = 32) or low (LE; n = 32) energy diets (ME = 100%, LE = 70% NRC recommendations). After parturition, half (n = 16) of each prepartum diet group received low (LE; n = 32) or high (HE = 130% NRC; n = 32) energy diets. At 30 d postpartum, cows were slaughtered 0 or 48 hr after CR. Hypothalami [preoptic area (POA), hypothalamus (HYP), stalk-median eminence (SME)] and pituitaries were collected. Basal and K(+)-induced release of GnRH from SME, and pituitary luteinizing hormone (LH) and follicle stimulating hormone (FSH) did not differ among groups (P greater than .05). Hypophyseal LH was correlated (P less than .01) with body condition score (BCS) at parturition and slaughter (r = .36 and .47, respectively). Prepartum LE diet increased (P less than .05) met-enkephalin in POA compared to prepartum ME (.59 +/- .05 vs. .44 +/- .04 pmol/mg) regardless of postpartum diet or suckling status. Concentrations of beta-endorphin in combined HYP + POA were decreased (P less than .05) by 48 hr CR (15.1 +/- 1.1 vs. 18.1 +/- 0.7 fmol/mg).(ABSTRACT TRUNCATED AT 250 WORDS)     

Retrospective analysis of the efficacy of different hormone treatments of cystic ovarian disease in cattle

Cystic ovarian disease in cows was treated either with a single intramuscular injection of 500 micrograms cloprostenol, a prostaglandin F2 alpha analogue, in 77 cases of luteal cysts or with 500 micrograms gonadorelin or 20 micrograms buserelin, gonadotrophin releasing hormone or its analogue (GnRH), in 116 cases of follicular cysts. Recovery was defined as the absence of cysts and the formation of a corpus luteum either with or without observed oestrus within 10 days after treatment with cloprostenol and 15 days after treatment with GnRH. Recovery occurred in 65 per cent and 52.6 per cent of cases, respectively, in average times of 4.9 and 19 days. Fifteen days after treatment with GnRH, 20 cows with luteinised cysts were treated with cloprostenol and 15 recovered in a mean of 20.4 days, while 10 which still had follicular cysts, were given GnRH and one recovered 31 days after the beginning of treatment. Another 27 cows, in which cysts became luteinised, were treated with cloprostenol seven days after treatment with GnRH to give quicker (average 11.5 days) but poor (48 per cent) recovery and with a higher rate (33 per cent) of recurrence of cysts. A progesterone releasing intrauterine device was used in 25 cases of cystic ovarian disease, some of which had been previously treated. Sixty-eight per cent recovered in an average of 15 days. The proportions of cows becoming pregnant to one to three inseminations after the different methods of treatment were similar (77 to 94 per cent).(ABSTRACT TRUNCATED AT 250 WORDS)